The Fabric of the Human Body

An Annotated Translation of the 1543 and 1555 Editions of “De Humani Corporis Fabrica” by

DANIEL H. GARRISON
MALCOLM H. HAST

• Modern layout enables the 21st-century reader to understand the complexity and pioneering nature of this milestone in medical history without the need of knowing Latin
• Different colors allow easy identification of notes relevant to both the 1543 and the 1555 editions
• Added notes for a never published third edition
• Up-to-date design and high-resolution digital scans of the woodcuts
• Nomina Anatomica and Terminologia Anatomica for the first time included to provide Vesalius’ descriptions with modern medical terminology
• Prefaces by the translators and introductions by medical historians Vivian Nutton and Nancy Siraisi

Special pre-publication offer until September 2013

www.vesalius-fabrica.com
Chemotherapy

International Journal of Experimental and Clinical Chemotherapy

Founded 1959 as 'Chemotherapia' by H.P. Kuemmerle and P. Rentchnick
Continued by H. Schönfeld (1968–2001)

Editor-in-Chief

F. Sörgel, Nürnberg-Heroldsberg

Editorial Board

C. Chiesa, Rome
S. Horkovics-Kovats, Kundl
S. Kohno, Nagasaki
C. Landersdorfer, Melbourne, Vic.
R.C. Moellering Jr., Boston, Mass.
K.G. Naber, Straubing
R. Nau, Göttingen
D. Nix, Tucson, Ariz.
P. Preziosi, Rome
M. Wilhelm, Nürnberg
F. Van Bambeke, Brussels

The founder of chemotherapy

Paul Ehrlich
1854–1915

Printed in Switzerland
on acid-free and non-aging
paper (ISO 9706) by
Reinhardt Druck, Basel

Appears bimonthly:
1 volume per year
(6 issues)
Chemotherapy

Guidelines for Authors

Submission
Only original papers written in English are considered for publication. Manuscripts should be submitted to 'Chemotherapy' online. For specific instructions on how to prepare a manuscript for submission, you are encouraged to view the guidelines at www.karger.com/che, where you will also find a link to the Submission Website. Names, postal and e-mail addresses of four experts in the appropriate area of research should accompany each manuscript. Selected scientists(s) will be invited to act as referee(s). Referees suggested should not be from the same institution as the author and should have expert knowledge of the subject. Should you have any problems with your submission, please contact:

Prof. F. Sörgel
S. Karger AG
Editorial Office 'Chemotherapy'
PO Box
CH–4009 Basel (Switzerland)
Tel. +41 61 306 1361
Fax +41 61 306 1434
E-Mail che@karger.com

Mailing address for courier deliveries only:
Allschwilerstr. 10
CH–4055 Basel (Switzerland)

Conditions
All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of 'Chemotherapy' and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Arrangement
Lines should be numbered on the margin.

Title page: The first page of each paper should indicate the title, the authors' names, the institute where the work was conducted, and a short title for use as running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Keywords: Please supply 3–10 key words in English that reflect the content of the paper.

Abstract: Each paper needs an abstract of up to 150 words structured with subheadings as follows: Background, Methods, Results, Conclusion(s).

Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate sheets. Tables require a heading and figures a legend, also prepared on a separate sheet. For the reproduction of illustrations, only good drawings and original photographs can be accepted; negatives or photocopies cannot be used. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations on one block for reproduction (max. size 180 × 223 mm) or provide crop marks. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1200 dpi.

Color illustrations

Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.– per page.

References: In the text, identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as ‘unpublished data’ and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples
(b) Papers published only with DOI numbers: Theoharis TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000638588.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. Orders reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

Author’s Choice™
Karger’s Author’s Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3000.–, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

NIH-Funded Research
The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author’s Choice™ service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH’s Public Access Policy is available at http://publicaccess.nih.gov/FAQ.html#1

Self-Archiving
Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution's servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher’s version, and must acknowledge the publisher’s copyright. Authors selecting Karger’s Author’s Choice™ feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.

Page Charges
There is no page charge for papers of 3 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.–. The allotted size of a paper is equal to approx. 9 manuscript pages (including tables, illustrations and references).

Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer’s errors, are charged to the author.

Reprints
Orders forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
47. Wissenschaftliche Tagung der Deutschsprachigen Mykologischen Gesellschaft e.V.
5. - 7. September 2013, Theologicum Tübingen

Themen
- Klinische Mykologie
- Pathogenese
- Therapie
- Dermatomykosen
- Veterinärmykologische Aspekte
- Richtlinien Bundesärztekammer

Tagungsleitung
Prof. Dr. med. Martin Schaller
Universitäts-Hautklinik
Klinikum der Universität Tübingen
Liebermeisterstr. 25 · 72076 Tübingen

Auskunft und Anmeldung
COCS GmbH - Congress Organisation C. Schäfer
Rosenheimer Str. 145c · 81671 München
Telefon: 089 - 89 06 77 - 0
E-Mail: katharina.meusel@cocs.de

www.dmykg.de oder www.cocs.de
65th Annual Meeting of the German Society for Hygiene and Microbiology

Annual Meeting of the German Society for Infectiology (dgi) e. V.

22–25 September 2013

University of Rostock • Rostock

Conference Presidents
Prof. Dr. Andreas Podbielski
University of Rostock

Prof. Dr. Ivo Steinmetz
Ernst-Moritz-Arndt University Greifswald

Prof. Dr. Winfried V. Kern
University Hospital of Freiburg
Where do we come from? Is our destiny determined by the genes we inherit? Do we all see the same blue color when we look at the sky? In this book Gottfried (Jeff) Schatz, the world-renowned biochemist, gives lucid – albeit often surprising – answers to universal questions and takes the reader on a fascinating journey of discovery across the boundaries of scientific disciplines. With passion and a keen sense of wonder he draws on philosophy, cultural history and art to formulate his reflections on the mystery of life. The key to understanding life is to be found in its chemistry, and he proves that this is no dry endeavor and certainly not devoid of beauty. The result is a collection of eloquently and poetically written essays dealing with key issues in the natural sciences. It will appeal not only to scientists, but also to all inquisitive minds, regardless of educational and professional background.
Contents

See the journal website for contents
This peer-reviewed online-only journal publishes original case reports covering the entire spectrum of oncology, including prevention, diagnosis, treatment, toxicities of therapy, supportive care, quality-of-life, and survivorship issues. The journal will also accept case reports dealing with the use of novel technologies, both in the arena of diagnosis and treatment. Supplementary material is welcomed. The intent of the journal is to provide clinicians and researchers with a tool to disseminate their personal experiences to a wider public as well as to review interesting cases encountered by colleagues all over the world.

Universally used terms can be searched across the entire growing collection of case reports, further facilitating the retrieval of specific information.

Following the open access principle, the entire contents can be retrieved at no charge, guaranteeing easy access to this valuable source of anecdotal information at all times.
Microbiology

475 One-Year Surveillance of ESKAPE Pathogens in an Intensive Care Unit of Monterrey, Mexico

482 Oxacillin Resistance and Antimicrobial Susceptibility Profile of Staphylococcus saprophyticus and Other Staphylococci Isolated from Patients with Urinary Tract Infection
Ferreira, A.M.; Bonesso, M.F.; Mondelli, A.L.; Camargo, C.H.; Cunha, M.L.R.S. (Botucatu)

Experimental Chemotherapy

445 Chemotherapy and Radiotherapy Downregulate the Activity and Expression of DNA Methyltransferase and Enhance Bcl-2/E1B-19-kDa Interacting Protein-3-Induced Apoptosis in Human Colorectal Cancer Cells

Clinical Studies

419 Risk Factors for Predicting Severe Neutropenia Induced by Amrubicin in Patients with Advanced Lung Cancer

426 Prognostic Significance of Serum Levels of Vascular Endothelial Growth Factor and Insulin-Like Growth Factor-1 in Advanced Gastric Cancer Patients Treated with FOLFOX Chemotherapy
Oh, S.Y.; Kwon, H.-C.; Kim, S.H.; Lee, S.; Lee, J.H. (Busan); Graves, C.A.; Camphausen, K. (Bethesda, Md.); Kim, H.-J. (Busan)

435 Acute Cerebrovascular Accident after Cisplatin Treatment in a Patient Taking Letrozole
Digkia, A.; Voutsadakis, I.A. (Lausanne)

439 Optimal Dose Period for Indisetron Tablets for Preventing Chemotherapy-Induced Nausea and Vomiting with Modified FOLFOX6: A Randomized Pilot Study
Nakatsumi, H. (Wakkanai/Sapporo); Komatsu, Y.; Yuki, S. (Sapporo); Sogabe, S. (Kushiro); Tatedaya, M.; Muto, S. (Tomakomai); Kudo, M. (Sapporo); Kato, K. (Iwamizawa); Miyagishima, T. (Kushiro); Uebayashi, M. (Kitami); Meguro, T.; Oba, K.; Asaka, M. (Sapporo)

454 A Retrospective Study of the Novel Combination of Paclitaxel and S1 for Pretreated Advanced Non-Small Cell Lung Cancer

461 Clinical Studies on the Treatment of Cancer Cachexia with Megestrol Acetate plus Thalidomide
Wen, H.-S.; Li, X.; Cao, Y.-Z.; Zhang, C.-C.; Yang, F.; Shi, Y.-M.; Peng, L.-M. (Ningbo)

468 Comparative Efficacy of Sunitinib versus Sorafenib as First-Line Treatment for Patients with Metastatic Renal Cell Carcinoma

492 Acknowledgement to the Reviewers
494 Contents Vol. 58, 2012